VHCDR2 has the sequence set forth in SEQ ID NO: 5; and

VHCDR3 has the sequence set forth in SEQ ID NO: 6.

3. The specific binding molecule for use according to claim **1** or **2**, wherein said specific binding molecule is an antibody or fragment thereof.

4. The specific binding molecule for use according to claim **3**, wherein said antibody or fragment thereof is humanised.

5. The specific binding molecule for use according to claim **3** or **4**, wherein said antibody is a monoclonal antibody, or said antibody fragment is an Fab, Fab' or $F(ab')_2$ antibody fragment or an scFv molecule.

6. The specific binding molecule for use according to claim **5**, wherein said antibody or fragment thereof comprises:

i) a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 9 or 10, or an amino acid sequence having at least 70% sequence identity thereto; and

ii) a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 11 or 12, or an amino acid sequence having at least 70% sequence identity thereto.

7. The specific binding molecule for use according to claim **6**, wherein said specific binding molecule is a monoclonal antibody comprising:

i) a light chain comprising the amino acid sequence set forth in SEQ ID NO: 13, or an amino acid sequence having at least 70% sequence identity thereto; and

ii) a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 14, or an amino acid sequence having at least 70% sequence identity thereto.

8. The specific binding molecule for use according to claim **6**, wherein said specific binding molecule is a monoclonal antibody comprising:

i) a light chain comprising the amino acid sequence set forth in SEQ ID NO: 15, or an amino acid sequence having at least 70% sequence identity thereto; and

ii) a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 16, or an amino acid sequence having at least 70% sequence identity thereto.

9. The specific binding molecule for use according to any one of claims **1** to **8**, wherein said cancer expresses Anx-A1.

10. The specific binding molecule for use according to claim **9**, wherein Anx-A1 is expressed on the surface of cells of said cancer.

11. The specific binding molecule for use according to any one of claims **1** to **10**, wherein said cancer is resistant to one or more chemotherapeutic agents.

12. The specific binding molecule for use according to claim **11**, wherein said cancer is multi-drug resistant.

13. The specific binding molecule for use according to claim **11** or **12**, wherein said cancer is resistant to platinum-based chemotherapeutic agents.

14. The specific binding molecule for use according to any one of claims **11** to **13**, wherein said cancer is resistant to cisplatin; adriamycin and/or tamoxifen.

15. The specific binding molecule for use according to any one of claims **1** to **14**, wherein said treatment further comprises the administration of a second therapeutic agent to said subject.

16. The specific binding molecule for use according to claim **15**, wherein said second therapeutic agent is a chemotherapeutic agent.

17. The specific binding molecule for use according to claim **16**, wherein said chemotherapeutic agent is a cytotoxic agent.

18. The specific binding molecule for use according to any one of claims **1** to **17**, wherein said subject is a human.

19. The specific binding molecule for use according to any one of claims **1** to **18**, wherein said cancer is selected from breast cancer, colorectal cancer, ovarian cancer, lung cancer and pancreatic cancer.

20. A method of treating cancer in a subject, comprising administering to said subject a specific binding molecule as defined in any one of claims **1** to **8**.

21. The method of claim **20**, wherein said cancer, treatment and/or subject is as defined in any one of claims **9** to **19**.

22. Use of a specific binding molecule in the manufacture of a medicament for the treatment of cancer in a subject, wherein said specific binding molecule is as defined in any one of claims **1** to **8**.

23. The use of claim **22**, wherein said cancer, treatment and/or subject is as defined in any one of claims **9** to **19**.

24. A kit comprising a specific binding molecule as defined in any one of claims **1** to **8** and a chemotherapeutic agent.

25. A product comprising a specific binding molecule as defined in any one of claims **1** to **8** and a second therapeutic agent for separate, simultaneous or sequential use in the treatment of cancer in a subject.

26. The product for use according to claim **25**, wherein said cancer, second therapeutic agent and/or subject is as defined in any one of claims **9** to **14** or **16** to **19**.

* * * * *